Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Limited announces PD-1 cancer vaccine development update

ASX Announcement

PD-1 cancer vaccine development update

  • New PD-1 cancer vaccine named KEY-Vaxx
  • Phase 1 planning well advanced
  • Preclinical results in validated models of colorectal (colon) cancer demonstrate inhibitory cancer growth activity
MELBOURNE Australia 23 July 2018: Imugene Limited (ASX: IMU), a clinical stage immunooncology company is pleased to announce a development update of its newly acquired PD-1 cancer vaccine from Ohio State University. The check-point inhibitor cancer vaccine named KEY-Vaxx, demonstrates superior cancer growth inhibition compared with an industry-standard monoclonal antibody in validated models of colorectal (colon) cancer (CT26).


For further information please download PDF attached:

Download this document